Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1826-1832

  Martin, Julie ^a   Wang, Zhong Q ^b   Zhang, Xian H ^b   Wachtel, Deborah ^a   Volaufova, Julia ^c   Matthews, Dwight E ^a   Cefalu, William T ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM PICOLINATE; FATTY ACID; GLIPIZIDE; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; WEIGHT GAIN;

ADIPOSE TISSUE; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; PHENOTYPE; PICOLINIC ACIDS; WEIGHT GAIN;

EID: 33746601010     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0254     Document Type: Article

References (39)

1. Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins and combinations. Endocrinol Metab Clin North Am 34:77-98, 2005
2. Gibson JE, Taylor DA: Can claims, misleading information and manufacturing issues regulating dietary supplements be improved in the United States of America? J Pharmacol Exp Ther 314:939-944, 2005
3. Neuhouser ML: Dietary supplement use by American women: challenges in assessing patterns of use, motives and costs (Review). J Nutr 133: 1992S-1996S, 2003
4. Cefalu WT, Hu FB: Role of chromium in human health and in diabetes. Diabetes Care 27:2742-2751, 2004
5. American Diabetes Association: Standards of medical care in diabetes 2006. Diabetes Care 29 (Suppl. 1):S4-S42, 2006
6. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
7. Abumrad NN, Rabin D, Diamond MP, Lacy WW: Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism 30:936-940, 1981
8. 3-adrenoceptor and insulin resistance in obese postmenopausal women. J Clin Endocrinol Metab 83:4002-4005, 1998
9. Toth MJ, Sites CK, Cefalu WT, Matthews DE, Poehlman ET: Determinants of insulinstimulated glucose disposal in middle-aged, premenopausal women. Am J Physiol Endocrinol Metab 281:E113-E121, 2001
10. Ballor DL, Harvey-Berino JR, Ades PA, Cryan J, Calles-Escandon J: Decrease in fat oxidation following a meal in weight-reduced individuals: a possible mechanism for weight recidivism. Metabolism 45:174-178, 1996
11. Paschal DC, Bailey GC: Determination of chromium in urine with graphite furnace atomic absorption spectrometry using Zeeman correction. Atomic Spectroscopy 12:151-154, 1991
12. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C: Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. Clin Chem 40:1317-1321, 1994
13. Cefalu WT, Bell-Farrow AD, Wang ZQ, McBride D, Dalgleish D, Terry JG: Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. Drug Dev Res 44:1-7, 1998
14. Rossetti L: Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clin Invest Med 18:255-256, 1995
15. Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP, Kapoor A, Bell-Farrow A, Terry JG, Sobel BE: Effect of combination glipizide GITS/ metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care 25:2123-2128, 2002
16. Crawford V, Scheckenbach R, Preuss HG: Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. Diabetes Obes Metab 1:331-337, 1999
17. Campbell WW, Joseph LJ, Anderson RA, Davey SL, Hinton J, Evans WJ: Effects of resistive training and chromium picolinate on body composition and skeletal muscle size in older women. Int J Sport Nutr Exerc Metab 12:125-135, 2002
18. Lukaski HC, Bolonchuk WW, Siders WA, Milne DB: Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr 63:954-965, 1996
19. Hallmark MA, Reynolds TH, DeSouza CA, Dotson CO, Anderson RA, Rogers MA: Effects of chromium and resistive training on muscle strength and body composition. Med Sci Sports Exerc 28:139-144, 1996
20. Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rassanen T, Kumpulainen J, Pyorala K: Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. Br J Nutr 68:209-216, 1992
21. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786-1791, 1997
22. Amato P, Morales AJ, Yen SS: Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, non-obese, older men and women. J Gerontol A Biol Sci Med Sci 55:M260-M263, 2000
23. Offenbacher EG, Pi-Sunyer FX: Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29:919-925, 1980
24. Kaats GR, Blum K, Fisher JA, Adelman JA: Effects of chromium picolinate supplementation on body composition: a randomized, double-masked placebo-controlled study. Cur Ther Res 57:747-756, 1996
25. Kaats GR, Blum K, Pullin D, Keith SC, Woods R: A randomized, double-masked, placebo-controlled study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Curr Ther Res 59:379-388, 1998
26. Evans GW: The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosoc Med Res 11:163-180, 1989
27. Purnell JQ, Weyer C: Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2:33-47, 2003
28. UKPDS Group: UK Prospective Diabetes Study 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88 1995
29. Rampone AJ, Reynolds PJ: Obesity: thermodynamic principles in perspective. Life Sci 43:93-110, 1988
30. Webber J: Energy balance in obesity. Proc Nutr Soc 62:539-543, 2003
31. Institute of Medicine (IOM) Final Report: Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington, DC, National Academy Press, 2001, p. 197-223
32. Anderson RA, Kozlovsky AS: Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 41:1177-1183, 1985
33. Gargas ML, Norton RL, Paustenback DJ, Finley BL: Urinary excretion of chromium by humans following ingestion of chromium picolinate: implications for biomonitoring. Drug Metab Dispos 23:607-609, 1995
34. Clancy SP, Clarkson PM, DeCheke ME, Nosaka K, Freedson PS: Effect of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. Int J Sport Nut 4:142-153, 1994
35. Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, Terry JG: Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med 12:71-83, 1999
36. Jeejeebhoy KN: The role of chromium in nutrition and therapeutics and as a potential toxin. Nutr Rev 57:329-335, 1999
37. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-PowellK, McElduff A: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 28:1841-1842, 2005
38. Komorowski J, Juturu V: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance: response to Gunton et al (Letter). Diabetes Care 28:712-713, 2005
39. Kleefstra N, Houweling ST, Jansman FGA, Groenier KH, Gans ROB, Meyboom-de Jong B, Bakker SJL, Bilo HJG: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 29:521-525, 2006